Paraneoplastic Hyperleucocytosis in a Melanoma Patient After Initiation of Ipilimumab and Nivolumab Combination Therapy

Journal for ImmunoTherapy of Cancer - United Kingdom
doi 10.1186/s40425-018-0430-y
Full Text
Abstract

Available in full text

Date
Authors
Publisher

BMJ

Related search

Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2017English

Severe Hemophagocytic Lymphohistiocytosis in a Melanoma Patient Treated With Ipilimumab + Nivolumab

Journal for ImmunoTherapy of Cancer
OncologyMolecular MedicinePharmacologyCancer ResearchAllergyImmunology
2018English

Lung Brain Metastasis Pseudoprogression After Nivolumab and Ipilimumab Combination Treatment

Thoracic Cancer
MedicinePulmonaryRespiratory MedicineOncology
2018English

Retrospective Side Effect Profiling of the Metastatic Melanoma Combination Therapy Ipilimumab-Nivolumab Using Adverse Event Data

Diagnostics
Clinical Biochemistry
2018English

Long Term Remission and Cardiac Toxicity of a Combination of Ipilimumab and Nivolumab in a Patient With Metastatic Head and Neck Carcinoma After Progression Following Nivolumab Monotherapy

Frontiers in Oncology
Cancer ResearchOncology
2019English

Fatal Myocarditis and Rhabdomyositis in a Patient With Stage IV Melanoma Treated With Combined Ipilimumab and Nivolumab

Current Oncology
Oncology
2019English

Pcn184 - Cost-Effectiveness of Nivolumab Plus Ipilimumab in Advanced Melanoma

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Cost-Effectiveness of Nivolumab in Combination With Ipilimumab in First-Line Treatment of Advanced Melanoma in Sweden

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2016English

Safe Administration of Ipilimumab, Pembrolizumab, and Nivolumab in a Patient With Metastatic Melanoma, Psoriasis, and a Previous Guillain–Barré Syndrome

Case Reports in Oncological Medicine
Oncology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy